Monte Rosa Therapeutics, Inc.
GLUE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $513 | $290 | $359 | $950 |
| - Cash | $224 | $128 | $55 | $346 |
| + Debt | $43 | $46 | $47 | $0 |
| Enterprise Value | $331 | $208 | $351 | $604 |
| Revenue | $76 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $68 | -$6 | $0 | $0 |
| % Margin | 89.3% | – | – | – |
| EBITDA | -$73 | -$137 | -$109 | -$71 |
| % Margin | -96.5% | – | – | – |
| Net Income | -$73 | -$135 | -$109 | -$74 |
| % Margin | -96.1% | – | – | – |
| EPS Diluted | -0.98 | -2.63 | -2.3 | -1.59 |
| % Growth | 62.7% | -14.3% | -44.7% | – |
| Operating Cash Flow | $42 | -$44 | -$92 | -$59 |
| Capital Expenditures | -$4 | -$19 | -$13 | -$10 |
| Free Cash Flow | $38 | -$63 | -$105 | -$69 |